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Abstract
Background: Circulating levels of endothelin-1 are increased in sepsis and correlate with severity of
disease. A rapid and easy immunoassay has been developed to measure the more stable ET-1 precursor
peptides proET-1. The objective of this study was to assess the diagnostic and prognostic value of proET-
1 in a prospective cohort of mainly septic patients with community-acquired pneumonia.
Methods: We evaluated 281 consecutive patients with community acquired pneumonia. Serum proET-1
plasma levels were measured using a new sandwich immunoassay.
Results: ProET-1 levels exhibited a gradual increase depending on the clinical severity of pneumonia as
assessed by the pneumonia severity index (PSI) and the CURB65 scores (p < 0.001 and p < 0.01). The
diagnostic accuracy to predict bacteraemia of procalcitonin (AUC 0.84 [95% 0.74–0.93]) was superior than
C-reactive protein (AUC 0.67 [95%CI 0.56–0.78]) and leukocyte count (AUC 0.66 [95%CI 0.55–0.78]) and
in the range of proET-1(AUC of 0.77 [95%CI 0.67–0.86]). ProET-1 levels on admission were increased in
patients with adverse medical outcomes including death and need for ICU admission. ROC curve analysis
to predict the risk for mortality showed a prognostic accuracy of proET-1 (AUC 0.64 [95%CI 0.53–0.74]),
which was higher than C-reactive protein (AUC 0.51 [95%CI 0.41–0.61]) and leukocyte count (AUC 0.55
[95%CI 0.44–0.65]) and within the range of the clinical severity scores (PSI AUC 0.69 [95%CI 0.61–0.76]
and CURB65 0.67 [95%CI 0.57–0.77]) and procalcitonin (AUC 0.59 [95% 0.51–0.67]). ProET-1
determination improved significantly the prognostic accuracy of the CURB65 score (AUC of the combined
model 0.69 [95%CI 0.59–0.79]). In a multivariate logistic regression model, only proET1 and the clinical
severity scores were independent predictors for death and for the need for ICU admission.
Conclusion: In community-acquired pneumonia, ET-1 precursor peptides correlate with disease severity
and are independent predictors for mortality and ICU admission. If confirmed in future studies, proET-1
levels may become another helpful tool for risk stratification and management of patients with community-
acquired pneumonia.
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Background
Endothelin-1 (ET-1) is a potent vasoconstrictor agent,
synthesized mainly by endothelial cells [1,2]. In the exper-
imental setting, endotoxaemia induces the expression of
endothelin precursors (prepro-Endothelin) mRNA in the
heart and the lung [2,3]. In humans, elevated plasma lev-
els of mature ET-1 are found during systemic infections
and increased plasma ET-1 levels correlate with mortality
risk [3-5]. In addition, animal studies demonstrated ben-
eficial effects of ET-1 antagonism by using a selective ET
receptor antagonist during septic shock [6-9]. Regrettably,
the analytical reliability of ET-1 measurements is cumber-
some because it is instable at room temperature and is
rapidly cleared from the circulation limiting its use in clin-
ical routine. Recently, a new sandwich immunoassay has
been introduced that measures the more stable precursor
fragments proET-1 [10,11]. Unlike the mature peptide,
these precursors can be detected for hours in the circula-
tion. Because of the stoichiometric generation, this "pro-
hormone" correlates with the release of the active peptide
[10], a condition similar to that of insulin and C-peptide.
Thus, these precursor peptides can be used to indirectly
measure the release of mature ET-1 in physiological and
pathological conditions.
At present there are no clinical data available regarding the
release of proET-1 during severe systemic infections other
than sepsis[12]. As community-acquired pneumonia
(CAP) is the most important precursor of sepsis, we
hypothesize that circulating proET-1 levels are increased
during the acute illness and might predict adverse out-
come in a well-defined cohort of 281 patients with CAP
requiring hospitalization.
Methods
Setting and Study population
The present study evaluated data and available plasma
samples from 281 patients admitted to the emergency
department with CAP from November 2003 through Feb-
ruary 2005 [13]. The primary endpoint of the study was
antibiotic stewardship guided by procalcitonin as com-
pared to standard recommended guidelines [13]. A prede-
fined secondary endpoint was the assessment of
prognostic factors and biomarkers in CAP. A detailed
description of the study has been published elsewhere
[13]. Briefly, patients admitted to the University Hospital
Basel, Switzerland, a 950-bed tertiary care hospital with
suspected CAP and age > 18 years were consecutively
included in this study. Excluded were patients with cystic
fibrosis, active pulmonary tuberculosis, hospital-acquired
pneumonia and patients with severe immuno-suppres-
sion. Patients were examined on admission to the emer-
gency department by a resident supervised by a board-
certified specialist in Internal Medicine. Baseline assess-
ment included clinical data and vital signs, assessment of
patients' functional status using a visual analogue scale,
comorbid conditions, and routine blood tests. In all
patients, the Pneumonia Severity Index (PSI) and the
CURB65 score were calculated [14]. Forty-nine percent of
the patients [N = 138] were randomized to receive antibi-
otic treatment according to procalcitonin guidance and
51% patients [N = 143] were allocated to the control
group. Treatment allocation did not have a significant
impact on all-cause mortality (OR 0.85 [95%CI: 0.42–
1.74], p = 0.67) or admission to the ICU (OR 0.85
[95%CI: 0.48–1.49], p = 0.571) and was thus not consid-
ered any further in this analysis.
CAP was defined by the presence of recently acquired res-
piratory signs, core body temperature >38.0°C, ausculta-
tory findings of abnormal breath sounds or rales,
leukocyte count >10 or <4 × 109 cells L-1 and an infiltrate
on chest radiograph [15]. Chest radiographs were
screened by the physician in charge and reviewed by a sen-
ior radiologist, unaware of clinical and laboratory find-
ings.
The study was approved by the institutional review board
(Ethikkommission beider Basel, EKBB) and written
informed consent was obtained from all included
patients. All data were held and analyzed by the authors.
Outcome
For outcome assessment, a follow up examination was
planned 6 weeks after study inclusion. Patients were fol-
lowed-up for a median duration of 42 days [IQR 35–53].
Two patients did not complete the follow up and as the
resolution of illness was uneventful during the hospitali-
sation, the day of discharge was counted as the time point
of follow up. Patients who survived until follow-up were
counted as survivors, whereas patients who died within
the follow-up period were counted as non-survivors.
Adverse medical outcome for this analysis was defined as
death and need for Intensive Care Unit (ICU) admission
from any cause.
Microbial investigations
The laboratory workup for the patients with CAP has been
previously described [13]. Briefly, it included sputum
samples for Gram stain and culture, two blood samples
for culture and urine sample for detection of Legionella
pneumophila.
Measurements of proET-1 and other laboratory 
parameters
Pro-ET1 was batch-measured in the plasma with a new
sandwich immunoassay as described elsewhere (CT-
proET1, BRAHMS AG, Hennigsdorf, Berlin, Germany)
[10,11]. The assay (normal reference range 44.3 ± 10.6
pmol/l) has an analytical detection limit of 0.4 pmol/l. C-BMC Infectious Diseases 2008, 8:22 http://www.biomedcentral.com/1471-2334/8/22
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reactive protein was measured in EDTA plasma on a
Hitachi Instrument 917 (Roche Diagnostics, Rotkreuz,
Switzerland). Procalcitonin was measured using 20 to 50
µL of plasma or serum by a time-resolved amplified cryp-
tate emission (TRACE) technology assay (PCT Kryptor®,
B.R.A.H.M.S. AG, Hennigsdorf, Germany). The assay has
a functional assay sensitivity of 0.06 µg/L, 3 to 10-fold
above normal mean values.
Statistical analysis
Discrete variables are expressed as counts (percentage)
and continuous variables as medians and interquartile
Ranges (IQR) unless stated otherwise. Frequency compar-
ison was done by chi-square test. Two-group comparison
of normally distributed data was performed by Students t-
test. For multigroup comparisons, one-way analysis of
variance with least square difference for posthoc compar-
ison was applied. For data not normally distributed, the
Mann-Whitney-U test was used if only two groups were
compared and the Kruskal-Wallis one-way analysis of var-
iance was used if more than two groups were being com-
pared. Receiver-operating-characteristics were calculated
using STATA 9.2 (Stata Corp, College Station, Tex).
Thereby, outcomes were either survival until follow-up or
adverse medical outcome including death and need for
ICU admission until follow-up, respectively. To estimate
the potential clinical relevance of proET-1 measurements,
we used likelihood-ratio tests to determine whether logis-
tic regression models that included measurements of
proET-1 and PSI/CURB65 provided a significant better fit
than did logistic regression models limited to the PSI or
CURB65 alone. Correlation analyses were performed by
using Spearman rank correlation. Levels that were non-
detectable were assigned a value equal to the lower limit
of detection for the assay. All testing was two-tailed and P
values less than 0.05 were considered to indicate statistical
significance.
Results
Baseline parameters
The median age of the 281 patients was 74 years and 20
percent of patients were pretreated with antibiotics. Tem-
perature ≥ 38°C was present in 64 percent of patients.
Cough, increased sputum production and dyspnea, the
typical self-reported cardinal symptoms of CAP, were
present in 89, 74 and 75 percent of all patients, respec-
tively. Overall, 80 percent of patients had relevant comor-
bidities including chronic obstructive pulmonary disease
in 25 percent and coronary or hypertensive cardiopathy in
53 percent. The median PSI score at presentation to the
Emergency Department was 100 [IQR 77–124] points. 39
percent of all patients were in the low risk PSI classes 1, 2
and 3. The median CURB65 score was 2 [IQR 2–3] and 47
percent of patients were in the low risk classes 0 and 1. 97
percent of patients were hospitalized for more than one
night with a median length of hospital stay of 11 days
[IQR 7–17]. Blood culture collection was performed in 89
percent of patients and in 12 percent growth of microor-
ganisms was observed (S. pneumoniae (60%), S. aureus
(10%), E. coli (6%), Klebsiella pneumoniae (6%)). Detailed
baseline characteristics of the study population are sum-
marized in Table 1.
ProET1 levels at presentation and recovery and 
correlation with disease severity
ProET1 (pmol/L) levels were significantly higher at hospi-
tal admission as compared to recovery (108.1 [IQR 99.3–
117.0] vs 70.1 [IQR 64.6–71.5], p < 0.0001 (Figure 1). On
admission, pro-ET1 levels significantly increased with
increasing severity of CAP as determined by the PSI scores
(Figure 2) and the CURB65 (Figure 3) score (p < 0.001
and p < 0.01). Median proET1 levels showed an about 2-
fold increase from patients with PSI class 1 to PSI class 5,
and a 0.4-fold increase from CURB65 class 0 to class 4,
respectively. This gradual increase was also present for
procalcitonin levels (p < 0.01, p < 0.01) and total leuko-
cyte count (p = 0.03, p = 0.004), but not for C-reactive
protein (p = 0.12, p = 0.61) and body temperature (p =
0.59, p = 0.42).
Table 1: Baseline Characteristics of the 281 Patients with CAP
Demographic characteristics
Age – years – [median-IQR] 74 [61–82]
Male sex – no. [%] 175 [62]
Coexisting illnesses – no. [%]
-Heart disease 149 [53]
-Renal dysfunction 76 [27]
-Chronic obstructive pulmonary disease 71 [25]
Clinical and laboratory findings
Clinical examination
-Confusion – no. [%] 25 [9]
-Systolic blood pressure mmHg- [median-IQR] 130 [112–142]
-Heart rate [bpm] – [median-IQR] 96 [82–110]
-Temperature [C°] – [median-IQR] 38.4 [37.7–39.2]
Laboratory findings – [median-IQR]
-C-reactive protein [mg/L) 132 [67–212]
-Procalcitonin [µg/L) 0.52 [0.20–2.45]
-Leukocyte count [× 109) 12.8 [9.1–16.8]
-ProET-1 [nmol/L) 94.6 [65.5–139.0]
Risk assessment
PSI points – [median-IQR] 100 [77–124]
PSI class – [median-IQR] 4 (3–4)
CURB65 – [median-IQR] 2 (1–2)
IQR denotes Interquartile Range, PSI Pneumonia Severity IndexBMC Infectious Diseases 2008, 8:22 http://www.biomedcentral.com/1471-2334/8/22
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ProET-1 levels showed significant correlations with renal
function (serum creatinine (r2 = 0.29, p < 0.0001) and
urea levels (r2 = 0.32, p < 0.0001)).
Pro-ET1 levels as diagnostic markers of bacterial infection
ProET-1 (pmol/L) levels were significantly higher in
patients with growth of bacteria in their blood culture (n
= 31) as compared to patients without growth of bacteria
(160.0 [IQR 95.7–218.0] vs 92.4 [IQR 63.7–128.5], p <
0.0001). ProET-1 levels significantly correlated with other
biomarkers of infection, i.e. procalcitonin (r2 = 0.31, p <
0.0001), C-reactive protein (r2 = 0.11, p < 0.0001) and
total leukocyte count (r2 = 0.07, p < 0.001).
The diagnostic accuracy of procalcitonin to predict bacter-
aemia (AUC 0.84 [95% 0.74–0.93]) was in the range of
ProET1 (AUC of 0.77 [95%CI 0.67–0.86], p = 0.21) and
superior than C-reactive protein (AUC 0.67 [95%CI 0.56–
0.78], p = 0.004) and leukocyte count (AUC0.66 [95%CI
0.55–0.78], p = 0.03). At an optimal cut-off of 154 pmol/
L, proET-1 had a sensitivity and specificity of 62% and
87% to predict bacteraemia and a positive and negative
predictive value of 37% and 95%. Likewise, procalcitonin
had a sensitivity and specificity of 86% and 74% and a
positive and negative predictive value of 27% and 98% at
an optimal cut-off of 1.34 µg/L.
Pro-ET1 levels as prognostic markers for outcome
At follow-up, an adverse medical outcome was noted in
61 patients (22%), including 35 deaths (13%) and 36
admissions to the ICU (13%). The reason for ICU reloca-
tions were need for invasive (n = 7) and non-invasive (n =
17) ventilation and hemodynamic stabilization because
of sepsis related hypotension (n = 12). Ten patients who
were admitted to the ICU subsequently died. In patients
who died during follow-up, proET-1 (pmol/L) levels on
admission were significantly higher as compared to levels
in survivors (124.0 [IQR 91.7–199.0] vs. 92.9 [IQR 65.0–
133.0], p = 0.008) (Figure 4). The respective values for
other markers of infection were not significant (for procal-
citonin: 0.61 [IQR 0.37–3.13] vs. 0.48 [IQR 0.18–2.45]
µg/L (p = 0.09), for C-reactive protein 152 [IQR 84–211]
vs. 132 [IQR 66–213] mg/L (p = 0.83) and for total leuko-
cyte count (13.5 [IQR 10.3–16.9] vs. 12.7 [IQR 9.0–16.7]
× 109/L (p = 0.35)). Moreover, proET1 levels but not pro-
calcitonin, C-reactive protein and leukocyte count were
ProET-1 levels increase according to disease severity as rep- resented by the CURB65 score (Confusion – Urea – Respira- tion rate – Blood pressure – Age 65) Figure 3
ProET-1 levels increase according to disease severity as rep-
resented by the CURB65 score (Confusion – Urea – Respira-
tion rate – Blood pressure – Age 65).
ProET-1 levels on admission and during/after recovery after  42 days [IQR 35–53] Figure 1
ProET-1 levels on admission and during/after recovery after 
42 days [IQR 35–53]. Data are shown as box plots.
ProET-1 levels increase according to disease severity as rep- resented by the PSI (Pneumonia Severity Index) Figure 2
ProET-1 levels increase according to disease severity as rep-
resented by the PSI (Pneumonia Severity Index).BMC Infectious Diseases 2008, 8:22 http://www.biomedcentral.com/1471-2334/8/22
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elevated in patients with an adverse medical outcome
consisting of either death or ICU admission (129.0 [IQR
94.6–191.0] vs. 88.2 [IQR 63.4–128.0] pmol/L, p <
0.0001) (Figure 5).
To assess the prognostic ability of proET-1 to predict (a)
death and (b) adverse medical outcome including death
and ICU admission, a receiver operating curve (ROC) was
calculated. The discriminatory ability to predict death and
adverse outcome of proET1 (AUC 0.64 [95%CI 0.53–
0.74] and AUC 0.69 [95% 0.61–0.77]) was significantly
better as compared to C-reactive protein (AUC 0.51 [95%
0.41–0.61] and AUC 0.58 [95% 0.51–0.66]) and leuko-
cyte count (AUC 0.55 [95% 0.44–0.65] and AUC 0.57
[95% 0.49–0.65]) and tended to be better as compared to
procalcitonin (AUC 0.59 [95% 0.51–0.67] and AUC 0.65
[95% 0.57–0.72]). As demonstrated in Table 2, the prog-
nostic accuracy of proET-1 was in the range of both clini-
cal assessment scores (PSI and CURB65). The optimal
prognostic accuracy for pro-ET1 was at a cut-off of 94
pmol/L. With this cut-off, the sensitivity to correctly pre-
dict mortality until follow-up was 71 percent, the specifi-
city 53 percent, the positive likelihood ratio (LHR+) 1.5
and the negative likelihood ratio (LHR-) 0.54. The respec-
tive values to predict adverse medical outcome were sev-
enty-seven, fifty-six percent and 1.8 and 0.4, respectively.
To estimate the additive value of proET-1 on the two clin-
ical scores to predict death and death and/or ICU admis-
sion, we calculated a multivariate logistic regression
model combing the PSI and proET1 and the CURB65 and
proET-1, respectively (Table 2). ProET-1 improved the
CURB65 score for the adverse medical outcome (p = 0.04)
and tended to improve it for death (p = 0.06). The combi-
nation of ProET-1 and the PSI score did not significantly
improve the prognostic value of the PSI score alone (AUC
0.71 [95%CI 0.62–0.76], p = 0.43 and AUC 0.75 [95%CI
0.68–0.81], p = 0.39).
When entering proET-1, procalcitonin, C-reactive protein,
and each of the clinical severity scores in a multivariate
logistic regression analysis, only proET-1 and a rise in one
of the two risk scores were independent predictors of
death and adverse medical outcome. Table 3 and Table 4
show the respective odds ratios and significance levels of
all variables for both outcomes.
Finally, to illustrate the capacity of proET-1 for risk assess-
ment for patients admitted to the emergency room, we
performed a comparison of survival (Figure 6) and
adverse medical outcome (Figure 7) in patients with
proET-1 below and above the optimal cut-off value of 94
pmol/l by Kaplan-Meier survival curves. Patients with
proET-1 levels above the optimal cut-off had significantly
lower survival rates and a higher risk for adverse medical
outcome as compared to patients with levels below the
cut-off of 94 pmol/L.
Discussion
The main findings of this study are that circulating levels
of ET-1 precursor peptides correlate with the severity of
CAP, as assessed by the PSI and CURB65 scores, resolve
during recovery of illness and predict the later finding of
bacteraemia in patients with CAP. ProET-1 levels on
admission are independent predictors of short term mor-
tality and need for ICU admission with a moderate but
superior prognostic accuracy as compared to commonly
measured laboratory parameters. Importantly, proET-1
ProET-1 levels in patients with and without an adverse medi- cal outcome including death and/or need for ICU admission Figure 5
ProET-1 levels in patients with and without an adverse medi-
cal outcome including death and/or need for ICU admission.
ProET-1 levels in survivors and nonsurvivors Figure 4
ProET-1 levels in survivors and nonsurvivors.BMC Infectious Diseases 2008, 8:22 http://www.biomedcentral.com/1471-2334/8/22
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levels can improve the prognostic accuracy of the com-
monly used CURB65 score to predict adverse outcome.
ET-1 originates from a larger precursor peptide, which is
first proteolytically processed to big ET-1 and further
excised by the action of endothelin-converting enzyme
[2]. In this study, we assessed the precursor fragment of
ET-1, because proET-1 fragments are stable at room tem-
perature and can be detected for hours after the cleavage
in the circulation, in contrast to mature ET-1, which is
eliminated within minutes and therefore escapes detec-
tion in clinical routine[10,11].
CAP accounts for almost 10% of mortality and morbidity
in hospitalized patients in western countries [16]. The
majority of patients in our study fulfilled the clinical crite-
ria for sepsis. While different cytokines and toxins contrib-
ute to the extensive vasodilatation often seen in systemic
infections, ET-1 as the most potent human vasoconstric-
tor counteracts these effects on the endothelial system
assuring blood pressure homeostasis and blood supply to
the individual organs [1,2]. However, accumulating evi-
dence indicates that increased ET-1 levels as seen during
sepsis rather contribute to the disturbance in blood pres-
sure homeostasis causing multiorgan failure and eventu-
ally death [17]. Increased levels of mature ET-1 have been
found in different experimental and clinical models of
Table 2: Results of the receiver operating curve (ROC) characteristic plot analysis
Prediction of death (n = 35) in patients with CAP (n = 281)
Parameter AUC 95% CI P 
ProET-1 0.64 0.53–0.74
PSI score 0.69 0.61–0.76 0.32
PSI/proET-1 combined 0.71 0.62–0.76 0.04
CURB65 score 0.67 0.57–0.77 0.51
CURB65/proET-1 combined 0.69 0.59–0.79 0.16
Prediction of adverse outcome (n = 61) in patients with CAP (n = 281)
Parameter AUC 95% CI P 
ProET-1 0.69 0.61–0.77
PSI classes 0.71 0.65–0.78 0.57
PSI/proET-1 combined 0.75 0.68–0.81 0.06
CURB65 score 0.66 0.58–0.73 0.45
CURB65/proET-1 combined 0.69 0.62–0.77 0.75
CAP Community-acquired Pneumonia, AUC, Area Under the Curve; CI, Confidence Interval, PSI Pneumonia Severity Index, CURB65 Confusion – 
Urea – Respiration rate – Blood pressure – Age 65
Table 3: Multivariate regression analysis for the prediction of death
Prediction of mortality in multivariate regression analysis including the PSI score in patients with CAP (n = 281)
Predictor Odds ratio (95% CI) P-value
ProET-1 1.006 (1.0010–1.0011) 0.018
PSI 2.113 (1.308–1.412) 0.002
Procalcitonin 0.962 (0.901–1.026) 0.246
C-reactive protein 0.998 (0.993–1.001) 0.274
Prediction of mortality in multivariate regression analysis including the CURB65 score in patients with CAP (n = 281)
Predictor Odds ratio (95% CI) P-value
ProET-1 1.007 (1.001–1.011) 0.010
CURB65 1.859 (1.214–1.847) 0.004
Procalcitonin 0.967 (0.910–1.026) 0.265
C-reactive protein 0.998 (0.993–1.001) 0.49BMC Infectious Diseases 2008, 8:22 http://www.biomedcentral.com/1471-2334/8/22
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sepsis [5,12,18,19]. We found increased levels of proET-1
in our patients with CAP depending on disease severity
and a decrease of proET-1 levels during recovery. In addi-
tion, we found a significant relationship of proET-1 with
other markers of inflammation and infection. ProET-1
levels had a higher diagnostic accuracy with a high nega-
tive predictive value as compared to traditional biomark-
ers of infection (C-reactive protein and leukocyte count)
and in the range of procalcitonin to exclude growth of
bacteraemia in blood cultures.
Procalcitonin has been put forward as a useful marker for
predicting disease severity and outcome in patients with
pneumonia [20]. Notably, in our study procalcitonin lev-
els correlated with CAP severity as assessed by the PSI and
the CURB65 score, but procalcitonin did not reach the
prognostic accuracy of proET-1 or the clinical scores.
Based on our results, procalcitonin is rather a diagnostic
tool able to guide decisions on antibiotic therapy, whereas
proET-1 is a superior prognostic marker to predict severity
of disease.
Sepsis is frequently associated with organ deterioration,
especially renal and cardiopulmonary insufficiency [18].
Endothelin has been discussed as one of the main patho-
physiological mechanisms underlying renal vasoconstric-
tion during endotoxaemia [21]. Increased levels of ET-1
have been found during sepsis related renal insufficiency
and infusion of ET-1 has been shown to reduce renal and
splanchnic blood flow in healthy volunteers [2,22]. In
addition, receptor antagonism of ET1 has been suggested
Table 4: Multivariate regression analysis for the prediction of adverse outcome
Prediction of adverse medical outcome in multivariate regression analysis including the PSI score in patients with CAP (n = 281)
Predictor Odds ratio (95% CI) P-value
ProET-1 1.007 (1.002–1.001) 0.004
PSI 2.092 (1.434–3.051) <0.001
Procalcitonin 0.976 (0.950–1.004) 0.093
C-reactive protein 1.001 (0.998–1.004) 0.428
Prediction of adverse medical outcome in multivariate regression analysis including the CURB65 score in patients with CAP (n = 
281)
Predictor Odds ratio (95% CI) P-value
ProET-1 1.007 (1.003–1.012) 0.001
CURB65 1.536 (1.096–2.153) 0.013
Procalcitonin 0.978 (0.952–1.003) 0.093
C-reactive protein 1.001 (0.998–1.004) 0.443
Kaplan Meier Survival curves showing the incidence of death  in patients with proET-1 levels above and below 94 pmol/L Figure 6
Kaplan Meier Survival curves showing the incidence of death 
in patients with proET-1 levels above and below 94 pmol/L. P 
= log rank test.
Kaplan Meier Survival curves showing the incidence of  adverse medical outcome including death and/or ICU admis- sion in patients with proET-1 levels above and below 94  pmol/L Figure 7
Kaplan Meier Survival curves showing the incidence of 
adverse medical outcome including death and/or ICU admis-
sion in patients with proET-1 levels above and below 94 
pmol/L. P = log rank test.BMC Infectious Diseases 2008, 8:22 http://www.biomedcentral.com/1471-2334/8/22
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to improve renal perfusion and function during sepsis
[23]. Likewise, in our clinical study we found a significant
correlation of ET-1 precursor peptides with creatinine and
urea. ProET-1 levels may mirror both, the inflammatory
cytokine response correlated with the severity of pneumo-
nia, as well as the presence of disease-relevant comorbid-
ities, namely renal dysfunction.
In the assessment and management of CAP, knowledge of
prognostic factors is crucial to estimate the risk for adverse
medical outcome and, thus the need for hospitalization.
In this context, there is interest for new measurable
biomarkers mirroring distinct pathogenetic mechanisms
to predict severity and outcome in CAP. The utility of a
biomarker in this context is defined by the degree it
improves clinical decision making and adds timely infor-
mation beyond that of readily available information from
clinical examination [24]. Our retrospective study can not
provide such information, but may help to provide a
rationale for future prospective studies. The information
of a biomarker may provide new insights into the patho-
physiology and prognosis of the disease process facilitat-
ing risk stratification and monitoring of therapy as a
surrogate outcome measure. In the future, a biomarker
might help in delineating distinct populations of patients
with discrete pathologies – a prerequisite to enable the tar-
geted application of specific biologically rational thera-
pies, i.e. ET-1 blocking agents like bosentan (Tracleer®)
[6,8,24,25,7,8,26]. Our study demonstrates that ET-1 pre-
cursor peptides are of moderate diagnostic and prognostic
utility as early and independent risk predictor for death
and need for ICU admission in patients with CAP. In a
multivariate logistic model the combination of proET-1
and the CURB65 risk scores significantly improved the
prognostic accuracy of the new model. Because the prog-
nostic utility of a single proET1 measurement was only
moderate in this analysis, this biomarker should be
imbedded in existing clinical risk scores and may improve
their accuracy.
It is advisable to base the difficult task of prognostic
assessment and treatment decisions on several and not
only one parameter, each mirroring different pathophysi-
ological aspects. The findings of this study support and
extend other observational studies evaluating the benefit
of novel biomarkers (e.g. natriuretic peptides, adrenom-
edullin and vasopressin precursor peptides) in the diag-
nostic assessment and risk stratification of patients with
cardiovascular and infectious disease [27].
Some limitations should be considered in interpreting our
results. First, this is a preplanned post-hoc analysis of the
ProCAP study [13] and, thus, rather hypothesis-generat-
ing than definite. Second, the overall prognostic utility of
proET1 with an AUC of 0.64 is rather low reflecting the
considerable overlap between survivors and non-survi-
vors, which narrows the clinical applicability of proET1.
In addition, the number of events in this analysis is of
only moderate size limiting the statistical power. For both
reasons, our results need to be confirmed in future pro-
spective studies with medical outcome as the primary
endpoint.
Conclusion
In conclusion, systemic ET-1 precursor peptides correlate
with disease severity and short term outcome in patients
with CAP. Intervention studies are needed to show
whether proET-1 measurement improves risk prognosti-
cation and thus improves the clinical management of
patients with CAP.
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